Hyloris Reports 44% Revenue Growth Driven By Royalties In 2023
Company R&D Investment Pushes 47% Expenditure Increase
Belgian company Hyloris Pharmaceuticals has reported a 44% revenue increase in its 2023 results while doubling down on its long-standing ambition to have 30 portfolio assets in the near future.
